Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.54 USD
Change Today +0.0021 / 0.39%
Volume 794.0K
STEM On Other Exchanges
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

stemcells inc (STEM) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/15 - $1.39
52 Week Low
08/24/15 - $0.31
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for STEMCELLS INC (STEM)

stemcells inc (STEM) Related Businessweek News

No Related Businessweek News Found

stemcells inc (STEM) Details

StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system. The company has completed Phase I/II clinical trial for the treatment of chronic spinal cord injury; and Phase I clinical trial for the treatment of Pelizaeus-Merzbacher disease, as well as completed enrollment and treatment in its Phase I/II clinical trial in geographic atrophy of age-related macular degeneration that cause blindness in the elderly. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

69 Employees
Last Reported Date: 03/13/15
Founded in 1988

stemcells inc (STEM) Top Compensated Officers

Chief Executive Officer, Director, Member of ...
Total Annual Compensation: $789.5K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $607.5K
Executive Vice President of Scientific & Stra...
Total Annual Compensation: $457.3K
General Counsel and Secretary
Total Annual Compensation: $409.6K
Compensation as of Fiscal Year 2014.

stemcells inc (STEM) Key Developments

StemCells Inc. Announces the Six-Month Interim Results for the First Cohort in Its Ongoing Phase II Pathway Study

StemCells Inc. announced that the six-month interim results for the first cohort in its ongoing Phase II Pathway Study in cervical spinal cord injury (SCI) showed motor improvements in both strength and function. The assessment of motor function involved using tests of dexterity. Clinicians used both ISNCSCI (International Standards for Neurological Classification of Spinal Cord Injury) and GRASSP (Graded Assessment of Strength Sensibility and Prehension) measures to establish a pre-transplant baseline for each patient and to assess post-transplant progress. Based on six-month follow-up, for the first cohort, an overall pattern of motor improvement was detected in four of the six patients as measured by gains in both strength and function on the collective ISNCSCI and GRASSP outcomes. Additional highlights of the six-month interim results include: Muscle strength was improved in five of the six patients, Four of the five patients with gains in muscle strength also demonstrated improved performance on functional tasks assessing dexterity and fine motor skills, Four of the six patients had improvement in the spinal level of injury as defined by the ISNCSCI assessment; three upgraded one level and one upgraded two levels, Based on a Patient Global Impression of Change (PGIC) assessment, four of the six patients reported that their condition had improved post-transplant, Changes in muscle strength and function were observed around three months post-transplant, consistent with the onset of sensory improvements seen in the company's Phase I/II thoracic study.

StemCells Inc. - Special Call

To discuss the interim results from the Phase II clinical trial of HuCNS-SC cells in spinal cord injury

StemCells, Inc. Receives Extension From Nasdaq To Regain Compliance

On May 14, 2015, StemCells, Inc. received written notice from the Nasdaq Stock Market (Nasdaq) that the closing bid price for the company’s common stock had been below $1.00 per share for 30 consecutive business days, and that the company was therefore not in compliance with the requirements for continued inclusion on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The company was given 180 calendar days, or until November 10, 2015, to regain compliance with the minimum bid price requirement. On November 5, 2015, the company applied for an extension of the 180 calendar day compliance period under Nasdaq Listing Rule 5810(c)(3). The company meets the applicable market value of publicly held shares requirement for continued listing and all applicable standards for initial listing on the Nasdaq Capital Market, except for the bid price requirement. The company also provided its intent to cure the minimum bid price deficiency. On November 11, 2015, Nasdaq granted the company an additional 180 calendar days, or until May 9, 2016, to regain compliance with the bid price requirement.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STEM:US $0.54 USD +0.0021

STEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Athersys Inc $1.05 USD 0.00
Biorestorative Therapies Inc $4.25 USD 0.00
Cytori Therapeutics Inc $0.37 USD -0.0006
Neuralstem Inc $1.14 USD +0.01
Opexa Therapeutics Inc $4.09 USD 0.00
View Industry Companies

Industry Analysis


Industry Average

Valuation STEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 60.3x
Price/Book 8.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.9x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact STEMCELLS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at